Treatment of melanoma cells with BRAFV600E/K or pan-RAF inhibitors (PLX4032 or LY3009120) reduced shLZTR1-induced pERK activation (Fig. 4d), rendering further support for the role of BRAF kinase activity. Here, RAF1 is linked to melanoma.